Indivior PLC Ordinary Shares (INDV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Indivior PLC Ordinary Shares (INDV) has a cash flow conversion efficiency ratio of 0.198x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-40.93 Million) by net assets ($-207.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Indivior PLC Ordinary Shares - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Indivior PLC Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Indivior PLC Ordinary Shares for a breakdown of total debt and financial obligations.
Indivior PLC Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Indivior PLC Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Shida Shenghua Chem
SHG:603026
|
0.031x |
|
Cosan S.A
SA:CSAN3
|
0.125x |
|
Asia Cement Corp
TW:1102
|
0.033x |
|
Titan Cement International SA
BR:TITC
|
0.084x |
|
Tsinghuatongfang Co Ltd
SHG:600100
|
0.019x |
|
AUMOVIO N
XETRA:AMV0
|
N/A |
|
EO Technics Co. Ltd
KQ:039030
|
0.046x |
|
BrightGene Bio Medical Technology C
SHG:688166
|
0.010x |
Annual Cash Flow Conversion Efficiency for Indivior PLC Ordinary Shares (2016–2024)
The table below shows the annual cash flow conversion efficiency of Indivior PLC Ordinary Shares from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Indivior PLC Ordinary Shares market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-349.00 Million | $36.00 Million | -0.103x | +99.91% |
| 2023-12-31 | $2.76 Million | $-315.00 Million | -114.171x | -148962.80% |
| 2022-12-31 | $51.28 Million | $-3.93 Million | -0.077x | -104.47% |
| 2021-12-31 | $202.60 Million | $346.97 Million | 1.713x | +168.26% |
| 2020-12-31 | $82.00 Million | $-205.73 Million | -2.509x | -434.41% |
| 2019-12-31 | $209.00 Million | $156.80 Million | 0.750x | -82.89% |
| 2018-12-31 | $66.00 Million | $289.41 Million | 4.385x | +387.26% |
| 2017-12-31 | $-203.00 Million | $309.87 Million | -1.526x | -20.82% |
| 2016-12-31 | $-295.00 Million | $372.72 Million | -1.263x | -- |
About Indivior PLC Ordinary Shares
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more